Published in Cancer Weekly, May 10th, 2005
The multi-center phase 2 trial is designed to evaluate the effects of SPI-153 on hormonal levels, in particular testosterone, as well as objective anti-tumor effects. The trial will be conducted in Europe with the collaboration of AEterna Zentaris Inc. (AEZ), Spectrum's licensor of SPI-153 (D-63153).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.